GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » EV-to-EBITDA

CTNM (Contineum Therapeutics) EV-to-EBITDA : -7.07 (As of Oct. 31, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Contineum Therapeutics's enterprise value is $222.84 Mil. Contineum Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-31.52 Mil. Therefore, Contineum Therapeutics's EV-to-EBITDA for today is -7.07.

The historical rank and industry rank for Contineum Therapeutics's EV-to-EBITDA or its related term are showing as below:

CTNM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.07   Med: 16.99   Max: 22.68
Current: -7.07

During the past 3 years, the highest EV-to-EBITDA of Contineum Therapeutics was 22.68. The lowest was -7.07. And the median was 16.99.

CTNM's EV-to-EBITDA is ranked worse than
100% of 439 companies
in the Biotechnology industry
Industry Median: 9.55 vs CTNM: -7.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-10-31), Contineum Therapeutics's stock price is $16.76. Contineum Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.065. Therefore, Contineum Therapeutics's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Contineum Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Contineum Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics EV-to-EBITDA Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBITDA
- - -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only - - - - -7.45

Competitive Comparison of Contineum Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Contineum Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Contineum Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's EV-to-EBITDA falls into.



Contineum Therapeutics EV-to-EBITDA Calculation

Contineum Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=222.841/-31.524
=-7.07

Contineum Therapeutics's current Enterprise Value is $222.84 Mil.
Contineum Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics  (NAS:CTNM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Contineum Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=16.76/-0.065
=At Loss

Contineum Therapeutics's share price for today is $16.76.
Contineum Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.065.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Contineum Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.